Osteoporosis is estimated to affect 200 million women worldwide. In the U.S. alone, more than 15 million prescriptions for oral and intravenous bisphosphonates (BPs) are dispensed each year for the prevention and management of osteoporosis, and are also used to prevent bone complications in metastatic cancer.

BPs where recently found responsible for a severe side effect known as bisphosphonate-related osteonecrosis of the jaw (BRONJ), characterized by an area of exposed bone in the maxillofacial region.

With only 35% of cases that fully recover, prevention is critical for patients before starting BP therapy. In addition, as the inciting event is usually dental surgery, the risk for BRONJ must be evaluated in candidate patients already administrated with BPs, thus supporting dentists and oral surgeons in assessing the status of their BP-treated patients before starting dental treatment.

While BRONJ adversely impacts quality of life and produces significant morbidity in afflicted patients, there is no specific test for predicting its risk.

Micromedic, in collaboration with the University of Florida and the Sheba Medical Center, has identified a unique genetic profile which characterizes cancer patients at risk of developing BRONJ.